Shaughnessy J, Gabrea A, Ying Q, Brents, L, Zhan F, Tian E, Sawyer J, Barlogie B, Bergsagel PL, and Kuehl M Cyclin D3 at 6p21 is dysregulated by recurrent Ig translocations in multiple myeloma.  Blood, 98:217-223. (2001)

Bumm K, Zheng M, Bailey C, Zhan F, Chiriva–Internati M, Eddlemon P, Terry J, Barlogie B and Shaughnessy J.  CGO:  Utilizing and Integrating Gene Expression Microarrays in Clinical Research and Data-Management. Bioinformatics, 18: 327-328. (2002)

Zhan, F, Hardin, J, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, Van Rhee F, Fassas A, Tricot G, Crowley J, Barlogie B, and Shaughnessy J. Global Gene Expression Profiling Of Multiple Myeloma, Monoclonal Gammopathy Of Undetermined Significance And Normal Bone Marrow Plasma Cells. Blood, 99:1745-1757. (2002).

Shaughnessy J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Badros A, Zangari A, Fassas A, Morris C, Muwalla F, and Barlogie B. Prognostic Impact Of Cytogenetic And Interphase FISH Defined Chromosome 13 Deletion In Multiple Myeloma: Early Results Of Total Therapy II, Br J Haematol, 120:44-52 (2003).

Zhan F, Tian E, Bumm K, Smith R, Barlogie B, and Shaughnessy J. Gene Expression Profiling of Normal Human Plasma Cell Differentiation and the Classification Of Multiple Myeloma Based on Similarities to Distinct Stages of Late Stage B-Cell Development. Blood, 101: 1128-1140 (2003).

Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J. A Subset of Multiple Myeloma Harboring the t(4;14)(p16;q32) Translocation Lack FGFR3 Expression but Maintain an IGH/MMSET Fusion Transcript. Blood, 101:2374-6 (2003).

Zent C, Zhan F, Schichman S, Bumm K, Lin P, Chen B, and Shaughnessy J. The Distinct Gene Expression Profiles Of Chronic Lymphocytic Leukemia And Multiple Myeloma Suggest Different Anti-Apoptotic Mechanisms But Predict Only Some Differences In Phenotype. Leuk. Res., 27:765-74 (2003).

Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Zhan F, Fassas A, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Tricot G, Crowley J, and Barlogie B.  Continuous Absence Of Metaphase Abnormalities Especially of Chromosome 13 and Hypodiploidy Assures Long Term Survival In Multiple Myeloma Treated with Total Therapy I:  Interpreted in the Context of Gene Expression Profiling, Blood, 101:3849-3856 (2003).

Wu K, Orme L, Shaughnessy J, Jacobson J, Barlogie B, and Moore MAS. Telomerase and Telomere Length in Multiple Myeloma: Correlations with Disease Heterogeneity, Cytogenetic Status and Overall Survival. Blood, 101:4982-4989 (2003).

Tarte K, De Vos J, Zhan F, Klein B, and Shaughnessy J.  Gene Expression Profiling of Plasma Cells and Plasmablasts: Toward a Better Understanding of the Late Stages of B-Cell Differentiation, Blood, 102:592-600 (2003).

Shaughnessy J and Barlogie B. Interpreting the Molecular Biology and Clinical Behavior of Multiple Myeloma Through Global Gene Expression Profiling. Immunol. Rev., 194:140-63 (2003).

Shaughnessy J Jr. Primer On Medical Genomics. Part IX: Scientific And Clinical Applications Of DNA Microarrays-Multiple Myeloma As A Disease Model. Mayo Clin Proc. 8:1098-109 (2003).

Tian E, Zhan F, Walker R, Rasmussan E, Ma Y, Barlogie B, Shaughnessy J. The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma. N Eng J Med. 349:2483-2494 (2003).

Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J. Treatment of Multiple Myeloma. Blood. 103:20-32 (2004).

Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 64:1546-58 (2004).

Bergsagel P, Kuehl M, Zhan F, Sawyer J, Barlogie B, and Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 106:296-303. (2005).

Qiang Y-W, Walsh K, Yao L, Kedei N, Blumberg P, Rubin J, Tosato G, Shaughnessy J, and Rudikoff S. Wnts induce migration/invasion of myeloma plasma. Blood.106:1786-93. (2005)

Waddell, M, Page, D., Shaughnessy J. Predicting Cancer Susceptibility for Single Nucelotide Polymorphism Data: A Case Study in Multiple Myeloma. BIOKDD, (2005).

Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 354(10):1021-30. (2006)

Stewart JP, Shaughnessy JD Jr. Role of osteoblast suppression in multiple myeloma. J Cell Biochem. 98(1):1-13 (2006).

Carrasco R, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Zhan F, Deepak Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson K, Chin L, Shaughnessy Jr. J, Brennan C and DePinho R. High-resolution genomic profiles defines distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell, Cancer Cell. 4:313-25 (2006)

Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer J, Holmig K, Zangarri M, Pineada-Roman M, Van Rhee F, Cavallo F, Burington B, John Crowley J, Tricot G, Barlogie B, and Shaughnessy Jr. J.  Frequent Gain of Chromosome Band 1q21 in Plasma Cell Dyscrasias Detected by Fluorescence In Situ Hybridization: Incidence Increases from MGUS to Relapsed Myeloma and is Related to Prognosis and Disease Progression Following Tandem Stem Cell Transplantation. Blood, 108: 1724-1732 (2006)